ADI Launches Sensinel CPM System with FDA Clearance to manage chronic heart deseases

Analog Devices has received the U.S. Food and Drug Administration (FDA) clearance to launch its Sensinel Cardiopulmonary Management (CPM) System. This innovative wearable device offers a non-invasive and remote solution for capturing crucial cardiopulmonary measurements, particularly for chronic conditions like heart failure. Notably, this marks ADI's first FDA clearance in its distinguished 59-year history. Addressing Chronic Disease Burden: With over 6 million Americans currently living with heart failure and rising healthcare costs projected to reach nearly $70 billion by 2030, there's an urgent need for effective management solutions. The Sensinel CPM System aims to mitigate these challenges by providing early detection and remote monitoring capabilities, potentially reducing costly hospitalizations. Non-Invasive Wearable Design: The Sensinel CPM Wearable offers a user-friendly experience, requiring patients to wear it for just three to five minutes in a home care setting. Despite its compact size, the device captures comprehensive cardiopulmonary data, offering a convenient and non-intrusive solution for patients. Cloud-Based Data Analysis: Utilizing ADI's Sensinel CPM Cloud Platform and Intelligent Algorithms, captured data is securely uploaded and analyzed in real-time. This cloud-based approach enables care teams to access precise physiological indicators remot...